8-KLeadership Changes

CVS HEALTH Corp 8-K Report, Executive Changes (Jul 10, 2013)

Filed July 10, 2013For Securities:CVS

Summary

This 8-K filing from CVS Health Corp. (CVS) announces a significant change in its financial leadership. Eva C. Boratto, previously Senior Vice President of PBM Finance, has been appointed Senior Vice President – Controller and Chief Accounting Officer (CAO). This role was temporarily held by the CFO, David M. Denton, who will now fully concentrate on his CFO responsibilities. Ms. Boratto's promotion is effective immediately and comes with an increased salary and incentive compensation, reflecting her expanded duties. Investors should note this transition as it pertains to internal financial reporting and controls. Ms. Boratto's extensive experience, including nearly 20 years at Merck & Co., Inc., suggests a solid foundation for her new role. The company's decision to move these responsibilities back to a dedicated CAO, separate from the CFO's primary duties, could signal a focus on strengthening financial oversight and reporting processes.

Key Highlights

  • 1Eva C. Boratto appointed Senior Vice President – Controller and Chief Accounting Officer (CAO), effective immediately.
  • 2David M. Denton, CFO, relinquishes the interim Controller and CAO duties to focus solely on his CFO role.
  • 3Ms. Boratto's annual salary increased to $500,000 upon her appointment.
  • 4Her 2013 target annual cash incentive award increased to 55% of her salary.
  • 5Ms. Boratto will continue to participate in equity incentive plans at levels consistent with her prior position.
  • 6Ms. Boratto has nearly 20 years of experience, including significant roles at Merck & Co., Inc.
  • 7The appointment indicates a formalization of the CAO role separate from the CFO position.

Frequently Asked Questions

Ms. Boratto's appointment signifies a strengthening of CVS Health's financial leadership structure. By appointing a dedicated Chief Accounting Officer, the company is ensuring robust oversight and management of its accounting operations and financial reporting, allowing the CFO to concentrate on broader financial strategy and execution.

David M. Denton, the CFO, will now be able to dedicate his full attention to his primary responsibilities as Executive Vice President and CFO. He had temporarily assumed the Controller and CAO roles following a prior transition, and this change allows for a more focused approach to both positions.

Upon her appointment as Controller and CAO, Ms. Boratto's annual salary is increased to $500,000, and her 2013 target annual cash incentive award is set at 55% of her salary. She will continue to participate in equity incentive plans at levels consistent with her previous role.

Yes, Ms. Boratto brings extensive experience to the role. She has been with CVS Caremark since July 2010 and previously held executive finance and investor relations positions at Merck & Co., Inc. for nearly 20 years, demonstrating a strong background in financial management and corporate accounting.